Voltage-gated ion channels play crucial roles in both excitable and non-excitable cells. Therefore, they constitute interesting drug targets. About 15% of the drugs used to treat human diseases target ...

Current guideline recommendations for the use of beta-blockers after myocardial infarction without reduced ejection fraction are based on trials conducted before routine reperfusion, invasive care, ...

New research explains how low levels of the electrolyte sodium in the blood can disrupt the timing of the heartbeat in patients taking widely used rhythm-control medications such as flecainide, which ...

Steven Poelzing (left) and Gregory Hoeker, researchers at the Fralin Biomedical Research Institute at VTC, collaborated on a new study published in the journal Heart Rhythm revealing why low blood ...

In the notoriously expensive business of drug development, SiteOne Therapeutics made do with little. The biotechnology startup formed in 2010, aiming to create new, non-addictive pain relievers at a ...

Treatment for coronary artery disease (CAD) involves lifestyle changes alongside medications such as antiplatelets and statins. There are many different medications to treat CAD. Treatment for CAD is ...

N-methyl-D-aspartate receptors (NMDARs) are ligand-gated ion channels present at most excitatory synapses in the brain that play essential roles in cognitive functions including learning and memory ...

Last week, the Food and Drug Administration approved Journavx, the first non-addictive opioid-like pain medication. Scientific discoveries at Yale were key to the development of the drug. Journavx, ...

Note: On January 30, 2025 the FDA approved the first-in-class non-opioid analgesic Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults. The novel drug reduces pain by ...